IL23A and inclusion conjunctivitis: Nevertheless, IL23A, SPARCL1, and PDGFB may be key mediators driving pathological inflammation and fibrosis in trachoma, and molecules that inhibit their action could hold therapeutic potential in preventing scarring progression.